Cogstate Ltd (AU:CGS) has released an update.
Cogstate Ltd has announced a partnership with Medidata to deliver a unified solution for central nervous system disease assessments, marking a significant strategic expansion for the company. This collaboration is expected to boost Cogstate’s sales, with the first contract anticipated soon. Additionally, Cogstate’s recent financial performance shows promising growth, supported by a new share buyback initiative.
For further insights into AU:CGS stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
